Physician profile

Daniel J Fitzpatrick

Psychiatric/Mental Health (Nurse Practitioner) · Spokane, WA

NPI 1457508327

$386.12

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$212.13

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $166.11 2024
E.R. Squibb & Sons, L.L.C. $105.82 2021
Axsome Therapeutics, INC. $30.79 2023 Auvelity
Janssen Pharmaceuticals, INC $30.79 2022-2023 Invega Sustenna
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $18.67 2022
Otsuka America Pharmaceutical, INC. $17.06 2022
Neurocrine Biosciences, INC. $16.88 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel J Fitzpatrick

$386.12

in general payments reported 2019-2025

Years
2021-2024
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/10747239/daniel-j-fitzpatrick

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.